Tenax Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.72) Per Share (NASDAQ:TENX)

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Zacks Small Cap cut their Q2 2024 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a report issued on Monday, May 20th. Zacks Small Cap analyst J. Vandermosten now expects that the specialty pharmaceutical company will earn ($1.72) per share for the quarter, down from their prior forecast of ($1.09). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($7.96) per share. Zacks Small Cap also issued estimates for Tenax Therapeutics’ Q3 2024 earnings at ($1.59) EPS, Q4 2024 earnings at ($1.71) EPS and FY2024 earnings at ($7.73) EPS.

Separately, Roth Mkm reiterated a “buy” rating on shares of Tenax Therapeutics in a research note on Tuesday, February 20th.

Tenax Therapeutics Trading Down 1.9 %

NASDAQ:TENX opened at $3.55 on Wednesday. Tenax Therapeutics has a one year low of $3.44 and a one year high of $61.20. The stock has a 50-day simple moving average of $3.73 and a 200 day simple moving average of $11.65.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.